Experimental 'decoy' protects against SARS-CoV-2 infection
Medical Xpress· 1 day agoLed by researchers at NYU Grossman School of Medicine, the work is based on how the virus that causes COVID-19, SARS-CoV-2, uses its ...
Essential process for SARS-CoV-2 viral replication visualized
Phys.org· 1 day agoThe results, published in a paper appearing in the Journal of Biological Chemistry, could support the development of more efficient drugs to treat COVID-19. Retroviruses and many other
Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine...
Nature· 6 days agoAccess to vaccines against SARS-CoV-2 virus was limited in poor countries during the COVID-19 pandemic. Therefore, a low-cost mRNA vaccine ...
Arbutus to Present at Jefferies Healthcare Conference - Arbutus Biopharma (NASDAQ:ABUS)
Benzinga· 9 hours agoWARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
Green Monkey DNA Found in the mRNA Shots
Mercola· 15 hours agoIn the video1 above, Dr. Steven E. Greer interviews microbiologist Kevin McKernan — a former researcher and team leader for the MIT Human Genome project2...
QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
MSN News· 5 days agoQIAGEN N.V. QGEN recently announced that it will offer its premium enzymes as standalone solutions, giving researchers and business clients the freedom to design their own tests and workflows ...
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People...
Morningstar· 6 days agoGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the ...
Pfizer's PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe...
Benzinga· 6 days agoPfizer Inc. PFE announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 ...
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Morningstar· 1 day agoTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / May 30, 2023 /CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based ...
After Covid-19, can mRNA vaccines help with cancer as well?
Knowable Magazine via Yahoo News· 7 days agoThe pandemic put the technology, long in development, to the test. Here’s a look at the status of...
Yahoo Web Search
Trending Now
